Ben Mauro's Sci-Fi Epic 'HUXLEY' Launches Globally with Hardcover & Softcover Editions; New Trailer and Prequel 'The Oracle' Announced for October Release

11.6.2025 14:00:00 CEST | Business Wire | Press Release

Renowned concept artist and storyteller Ben Mauro, known for his work on major franchises such as Halo Infinite, Call of Duty, and Elysium, proudly announces the worldwide release of his acclaimed sci-fi graphic novel series, HUXLEY. The series is now available in hardcover and softcover editions through major retailers, including Amazon and bookstores globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610972522/en/

Screenshot from HUXLEY: THE ORACLE.

Set in the post-apocalyptic world of FURY-7, HUXLEY follows the journey of Max, a seasoned Ronin warrior, and his companions as they navigate a landscape dominated by ancient machines and rogue AI empires. The narrative combines cinematic world-building with mythic storytelling, appealing to fans of Dune, Ghost in the Shell, and Warhammer 40K.

In conjunction with the book launch, a new trailer has been released for the upcoming prequel, HUXLEY: The Oracle, offering a glimpse into the origins of the saga. The prequel, set to release in October 2025, delves deeper into the lore of the HUXLEY universe, exploring the rise of the Oracles—the enigmatic machine rulers of the wasteland—and the early days of the AI wars.

HUXLEY Oracle Trailer
https://www.youtube.com/watch?v=7nbOCqbkUA4

HUXLEY Hardcover
https://vol.co/collections/huxley
https://vol.co/collections/the-oracle

HUXLEY Softcover
https://www.thamesandhudsonusa.com/books/huxley-softcover
https://www.amazon.com/HUXLEY-Ben-Mauro

Ben Mauro's vision for HUXLEY extends beyond the pages of the graphic novel, encompassing a transmedia approach that includes games, animation, and collectibles. The franchise has garnered significant attention, with its cinematic teaser amassing over 3.6 million views on YouTube and a growing global fanbase.

“HUXLEY is the universe I’ve always dreamed of creating,” says Mauro. “It's a homage to the inspirations of my youth, reimagined for a new generation.”

HUXLEY is available now via Amazon and major retailers. For more information, updates, and to watch the new trailer, visit www.huxleysaga.com.

About HUXLEY

HUXLEY is a post-apocalyptic sci-fi universe set in the far future, where ancient machines, rogue AIs, and forgotten empires shape the fate of humanity. Spanning graphic novels, cinematic trailers, and future game and animation projects, HUXLEY blends mythic storytelling with AAA-level worldbuilding. With a rapidly growing global fanbase, it offers a rich transmedia experience designed for readers, gamers, and collectors alike.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610972522/en/

Contacts

Media Contact:
Ben Mauro
Benmauro@huxleysaga.com
www.huxleysaga.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.huxleysaga.
com&esheet=54270340&newsitemid=20250610972522&lan=en-US&anchor=www.huxleysaga.co
m&index=7&md5=121a8a1406bc40ad55c88612c9e76903

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom